In Cartilage Repair Histogenics Resets The Stage

In July Histogenics Corp. raised $49 million in a Series A recap round that will help it complete a Phase III clinical trial in articular cartilage repair. The deal also shows that Histogenics’ novel strategy for getting through the mid-stage funding gap was a success.